Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24767617 | 1.00 | TSHR (0.49) | TSHRCSNK1EGRM2SPHK1NR1I2 | |
| SCHEMBL1068393 | 0.98 | TSHR (0.50) | TSHRCSNK1EGRM2SPHK1NR1I2 | |
| SCHEMBL28300830 | 0.98 | TSHR (0.50) | TSHRCSNK1EGRM2SPHK1NR1I2 | |
| SCHEMBL24349584 | 0.98 | TSHR (0.50) | TSHRCSNK1EGRM2SPHK1NR1I2 | |
| SCHEMBL18557410 | 0.98 | TSHR (0.50) | TSHRCSNK1EGRM2SPHK1NR1I2 | |
| SCHEMBL28183514 | 0.95 | TSHR (0.45) | TSHRCSNK1EGRM2CPN1CPB2 | |
| SCHEMBL20921369 | 0.88 | TSHR (0.42) | TSHRGRM2NR1I2CPN1CPB2 | |
| SCHEMBL28710729 | 0.86 | NR1I2 (0.44) | CSNK1ENR1I2HTR2A | |
| SCHEMBL18922904 | 0.84 | CYP3A4 (0.42) | TSHRCPN1CPB2 | |
| SCHEMBL6429607 | 0.83 | TSHR (0.49) | TSHRCSNK1EGRM2SPHK1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-9760030-B2 | Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus | CANON KABUSHIKI KAISHA (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9662335-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | JAK3, JAK1, JAK2 | TSHR 3192/4885CSNK1E 1450/4885GRM2 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.